文献速递神经肿瘤

最大18F-FDOPA PET摄取变化率与非强化肿瘤体积预测低级别胶质瘤恶性转化和总生存

Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.
PubMed 文献 · J Neurooncol · 2020-01-24

研究纳入27例2003至2016年间至少接受2次18F-FDOPA PET和MRI扫描的低级别胶质瘤患者,评估最大标准化摄取变化率与非强化体积变化率对恶性转化和总生存的预测价值。采用年龄、治疗、FLAIR变化率和18F-FDOPA nSUVmax变化率的通用线性模型预测恶性转化,灵敏度与特异度均>67%(AUC=0.7556,P=0.0248)。PET摄取变化率是总生存的独立预测因素(HR=1.0242,P=0.0033)。

要点

  • 年龄、治疗、FLAIR变化率和18F-FDOPA nSUVmax变化率模型预测恶性转化AUC=0.7556,P=0.0248。
  • PET摄取变化率连续测量与总生存显著相关(HR=1.0212,P=0.0034),多变量分析中为独立预测因素(HR=1.0242,P=0.0033)。
  • 按FLAIR变化率、PET摄取变化率或两者分层均可预测总生存(HR分别为2.220、2.148、2.354)。

核心结论

  • 最大标准化18F-FDOPA PET摄取变化率,无论是否结合临床信息和肿瘤体积变化率,可能有助于预测低级别胶质瘤患者的恶性转化风险和估计残余生存。

研究设计与样本

  • 纳入27例低级别胶质瘤患者,2003年至2016年间至少接受2次18F-FDOPA PET和MRI扫描。
  • 比较组织学和分子亚型间的FLAIR体积变化率(uL/天)和最大标准化18F-FDOPA特异性摄取变化率(nSUVmax/月)。
  • 采用通用线性模型整合临床信息与MR-PET测量预测恶性转化,Cox单变量和多变量回归分析识别与总生存相关的影像和临床风险因素。

主要发现

  • 使用患者年龄、治疗、FLAIR变化率和18F-FDOPA nSUVmax的通用线性模型预测恶性转化,灵敏度和特异度均>67%(AUC=0.7556,P=0.0248)。
  • 总生存与PET摄取连续变化率显著相关(HR=1.0212,P=0.0034)。
  • Cox多变量分析证实PET摄取连续变化率是总生存的独立预测因素(HR=1.0242,P=0.0033)。
  • 按FLAIR变化率升高或降低分层(HR=2.220,P=0.025)、按PET摄取变化率分层(HR=2.148,P=0.0311)、按FLAIR和PET两者分层(HR=2.354,P=0.0135)均可预测总生存。

临床怎么用

  • 原文结论指出,最大标准化18F-FDOPA PET摄取变化率可能有助于预测低级别胶质瘤患者的恶性转化风险和估计残余生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine whether the rate of change in maximum 18F-FDOPA PET uptake and the rate of change in non-enhancing tumor volume could predict malignant transformation and residual overall survival (OS) in low grade glioma (LGG) patients who received serial 18F-FDOPA PET and MRI scans. METHODS: 27 LGG patients with ≥ 2 18F-FDOPA PET and MRI scans between 2003 and 2016 were included. The rate of change in FLAIR volume (uL/day) and maximum normalized 18F-FDOPA specific uptake value (nSUVmax/month), were compared between histological and molecular subtypes. General linear models (GLMs) were used to integrate clinical information with MR-PET measurements to predict malignant transformation. Cox univariate and multivariable regression analyses were performed to identify imaging and clinical risk factors related to OS. RESULTS: A GLM using patient age, treatment, the rate of change in FLAIR and 18F-FDOPA nSUVmax could predict malignant transformation with > 67% sensitivity and specificity (AUC = 0.7556, P = 0.0248). A significant association was observed between OS and continuous rates of change in PET uptake (HR = 1.0212, P = 0.0034). Cox multivariable analysis confirmed that continuous measures of the rate of change in PET uptake was an independent predictor of OS (HR = 1.0242, P = 0.0033); however, stratification of patients based on increasing or decreasing rate of change in FLAIR (HR = 2.220, P = 0.025), PET uptake (HR = 2.148, P = 0.0311), or both FLAIR and PET (HR = 2.354, P = 0.0135) predicted OS. CONCLUSIONS: The change in maximum normalized 18F-FDOPA PET uptake, with or without clinical information and rate of change in tumor volume, may be useful for predicting the risk of malignant transformation and estimating residual survival in patients with LGG.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Oughourlian TC, Yao J, Schlossman J, et al. Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. J Neurooncol. 2020. PMID: 31981013. doi:10.1007/s11060-020-03407-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。